Pfizer COVID-19 vaccine works against UK, South African mutations: study – New York Post

NEW YORK – Pfizer Inc and BioNTech’s COVID-19 vaccine appeared to work against a key mutation in the highly transmissible new variants of the coronavirus discovered in the UK and South Africa, according to a laboratory study conducted by the US drugmaker.

The not-yet peer-reviewed study by Pfizer and scientists from the University of Texas Medical Branch indicated the vaccine was effective in neutralizing the virus with the so-called N501Y mutation of the spike protein.

The mutation could be responsible for greater transmissibility and there had been concern it could also make the virus escape antibody neutralization elicited by the vaccine, said Phil Dormitzer, one of Pfizer’s top viral vaccine scientists.

The study was conducted on blood taken from people who had been given the vaccine. Its findings are limited, because it does not look at the full set of mutations found in either of the new variants of the rapidly spreading virus.

Dormitzer said it was encouraging that the vaccine appears effective against the mutation, as well as 15 other mutations the company has previously tested against.

“So we’ve now tested 16 different mutations, and none of them have really had any significant impact. That’s the good news,” he said. “That doesn’t mean that the 17th won’t.”

Dormitzer noted another mutation found in the South African variant, called the E484K mutation, is also concerning.

Sorgente articolo:
Pfizer COVID-19 vaccine works against UK, South African mutations: study – New York Post

User ID Campaign ID Link
d9a95efa0a2845057476957a427b0499 l-99999982 Cloud Realtime
d9a95efa0a2845057476957a427b0499 l-99999996 Service for LMS
d9a95efa0a2845057476957a427b0499 l-99999994 Marketing Automation
d9a95efa0a2845057476957a427b0499 l-99999984 Free Web Host